Business Wire

Data Presented at UEG Week 2023 Further Support the Potential of Celltrion’s Investigational Subcutaneous Infliximab CT-P13 SC in the Treatment of Inflammatory Bowel Disease


Celltrion Healthcare today presented Phase III data from the LIBERTY-CD and LIBERTY-UC clinical trials, for the investigational subcutaneous (SC) infliximab in inflammatory bowel disease (IBD) treatment at the United European Gastroenterology (UEG) Week 2023 in Copenhagen.1

Results from the LIBERTY studies, presented during a satellite symposium, evaluated the effectiveness of SC infliximab over placebo in patients with moderately to severely active Crohn's disease (CD) or ulcerative colitis (UC). SC infliximab had a similar safety profile to the placebo during the maintenance period. The proportion of patients who experienced adverse events (AEs), serious AEs, infection in the SC infliximab and placebo groups were generally comparable. No new safety concerns were identified.1

LIBERTY-CD and LIBERTY-UC are registrational studies currently under review by the U.S. FDA as part of a Biologics License Application (BLA) submission. If approved by the FDA, CT-P13 SC would be the first subcutaneous formulation of infliximab.

Post-hoc analyses of the LIBERTY-CD and LIBERTY-UC studies were presented as posters at UEG Week 2023. The first post-hoc analysis examined the possible use of SC infliximab treatment without immunosuppressants and the second evaluated dose escalation in patients with loss of treatment response.

The first post-hoc analysis supports the efficacy and safety of SC infliximab as a monotherapy without immunosuppressants for CD and UC patients. After 54 weeks, there were no statistical differences in efficacy outcomes between monotherapy and combination therapy with immunosuppressants. The overall safety profile during the maintenance period was also comparable between the two groups, suggesting limited benefit of combination therapy with immunosuppressants for IBD patients treated with SC infliximab.2

The second post-hoc analysis evaluated the impact of dose escalation of SC infliximab in managing the loss of response to treatment in IBD patients. The recommended dose for subcutaneous infliximab is 120 mg once every 2 weeks.3 Exploratory results suggest that dose escalation from 120mg to 240mg every two weeks may restore efficacy, while safety profiles, including immunogenicity and the incidence rate of adverse events, were shown to be comparable between patients with or without dose escalation. In both UC and CD studies, patients showed improvement in terms of clinical remission [24.7% (20/81) in UC and 53.8% (21/39) in CD] or endoscopic response [28.2% (11/39) in CD] after dose escalation. Compared to the first dose escalation visits, patients on dose escalation had a statistically significant reduction in modified Mayo score (in UC) and CDAI score (in CD) at Week 54.4

In a separate presentation at UEG Week 2023, real-world data on switching from intravenous (IV) to SC infliximab were evaluated. The findings may help support the practical application of this innovation.5

Stephen B. Hanauer, MD, medical director of the Digestive Health Center at Northwestern Medicine, and professor of medicine at the Feinberg School of Medicine said, “As a healthcare professional dedicated to improving the lives of IBD patients, I am excited to see further data that validate a subcutaneous treatment option allowing more patients in the U.S. to have greater control of their disease.”

Tom Nusbickel, Chief Commercial Officer at Celltrion USA said, “We have already seen the positive impact of subcutaneous infliximab on patients in Europe. We are committed to bringing SC infliximab to the U.S. to increase the therapeutic options for IBD once approved by the FDA which is to be marketed and sold by Celltrion USA.”

The European Commission authorized CT-P13 SC in 2020 for multiple indications including CD and UC. FDA approval decision for CT-P13 SC is anticipated within the fourth quarter of 2023.


About CT-P13 (biosimilar infliximab)
CT-P13 is developed and manufactured by Celltrion and was the world's first monoclonal antibody biosimilar of reference infliximab. It is indicated for the treatment of eight autoimmune diseases including Crohn’s disease (CD) and ulcerative colitis (UC). It was approved by the European Commission under the trade name Remsima® in September 2013 and launched in major EU countries in early 2015. The U.S. Food and Drug Administration approved CT-P13 in April 2016 under the trade name Inflectra®. Remsima® is authorized in over 100 countries worldwide as of January 2023, with a 55% market share in Europe in 2022.6

Subcutaneous infliximab (CT-P13 SC) has received EU marketing authorization for the treatment of patients with CD, UC, rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and psoriasis in adult patients. In the United States, CT-P13 SC is being reviewed through the new drug pathway by the U.S. Food and Drug Administration (FDA) for the treatment of CD and UC.

About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA Current Good Manufacturing Practice (cGMP) and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality, cost-effective solutions through an extensive global network that spans more than 110 different countries.

For more information, please visit:

About Celltrion USA
Celltrion USA is Celltrion Healthcare’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion currently has five biosimilars approved by the U.S. FDA: Inflectra® (infliximab-dyyb), Truxima® (rituximab-abbs), Herzuma® (trastuzumab-pkrb), Vegzelma®(bevacizumab-adcd), and Yuflyma®(adalimumab-aaty). Celltrion USA will continue to leverage Celltrion Healthcare’s unique heritage in biotechnology, supply chain excellence, and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients.

Important Safety Information

Please refer to the full Summary of Product Characteristics for full prescribing information for CT-P13 SC:


1 S. Schreiber. (2023, October). Phase 3 Clinical Trials with Subcutaneous Infliximab in Patients with IBD (LIBERTY-CD & UC). In S. Schreiber (Chair), IS-10 Refining the Journey in the Treatment of IBD with Subcutaneous Infliximab [Symposium]. UEG Week 2023, Copenhagen, Denmark.

2 S. Schreiber et al., Efficacy, safety and immunogenicity of Subcutaneous Infliximab (CT-P13 SC) monotherapy versus combination therapy with Immunosuppressants – Post hoc analysis of LIBERTY-CD study and LIBERTY-UC study. Poster PP0757 Presented at UEGW 2023.

3 European Medicines Agency. Subcutaneous Infliximab. Summary of product characteristics. 2023., Accessed October 2023

4 S. Danese et al., Subcutaneous Infliximab (CT-P13 SC) dose escalation as an option for managing the loss of response in Inflammatory Bowel Disease: Post hoc analysis of LIBERTY-UC study and LIBERTY-CD study. Poster MP362 Presented at UEGW 2023.

5 N. Mathieu. (2023, October). Insights from Clinical Practice: Switching from Intravenous to Subcutaneous Infliximab in Patients with IBD. In S. Schreiber (Chair), IS-10 Refining the Journey in the Treatment of IBD with Subcutaneous Infliximab [Symposium]. UEG Week 2023, Copenhagen, Denmark.

6 Celltrion, Inc. Fourth-Quarter and Full Year 2022 Earnings Release.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Dillon Olagaray
+1 209-663-3141

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New VCMI Guidance Opens Door for Corporate Carbon Credit Claims28.11.2023 11:36:00 CET | Press release

The Voluntary Carbon Markets Integrity Initiative (VCMI) has today released additional guidance for its Claims Code of Practice (Claims Code), enabling companies to make claims about their use of high-quality carbon credits. This guidance includes a Monitoring, Reporting and Assurance (MRA) Framework, a brand and associated mark for making ‘Carbon Integrity' Claims, and a beta version of an additional claim. Using the MRA framework and the ‘Carbon Integrity’ Claims branding, companies can now make Silver, Gold or Platinum Claims as outlined in the original Claims Code of Practice released in June. This means these companies can now make claims using high-quality carbon credits, directing finance to initiatives that mitigate climate change, and demonstrating that they are going above and beyond science-aligned emissions cuts. VCMI has also launched the beta version of a new claim – called the ‘Scope 3 Flexibility’ Claim - as a practical step to accelerate corporate climate action. Once

inDrive welcomes Stephen Kruger as Chief Technology and Product Officer28.11.2023 10:00:00 CET | Press release

inDrive, a global mobility and urban services platform, announces the appointment of Stephen Kruger as its Chief Technology and Product Officer. Stephen will be responsible for implementing inDrive’s technology and product development strategies as the company continues to expand into new geographies and business verticals. inDrive has built out its platform with geography-specific freight and courier offerings, as well as handyman services, in addition to its core ride-hailing business. The combined technology and product team is tasked with continuing to scale inDrive’s platform, implementing new product features to support growth and further diversification of the business. Welcoming Stephen to the team, inDrive founder and CEO Arsen Tomsky said: "Stephen's remarkable background in technology leadership aligns seamlessly with our vision for inDrive's future. His proven ability to drive organizational change and innovation will undoubtedly strengthen our position in the industry whil

Reply Awarded With Two 2023 AWS Partner Awards: System Integrator Partner of the Year EMEA and Energy and Utilities Partner of the Year Global28.11.2023 09:30:00 CET | Press release

Reply, a global systems integrator and consulting firm and AWS Premier Consulting partner, is excited to announce it is a recipient of two 2023 Geo and Global AWS Partner Awards, which recognize leaders around the globe playing a key role helping customers drive innovation and build solutions on Amazon Web Services (AWS). The Geo and Global AWS Partner Awards celebrate a wide range of AWS Partners, whose business models have embraced specialization, innovation, and cooperation over the past year. Geo and Global AWS Partner Awards recognize partners whose business models continue to evolve and thrive on AWS as they work with customers. A panel of AWS experts selected the winners based on strict criteria. Reply is excited to announce it has received: - Global Industry Partner of the Year – Energy and Utilities, which recognizes top AWS Partners with the AWS Energy Competency who help customers build and implement advanced solutions powered by AWS across the industry value chain. Leveragi

Regula Shares Identity Verification Trends to Shape 2024 and Beyond28.11.2023 09:00:00 CET | Press release

Staying ahead in ID verification ensures a secure and flourishing future for organizations. This is why Regula experts are releasing their forecast for the trends for 2024 and beyond. Based on an analysis of recent developments in the IDV area, the experts highlighted nine trends, with those revolving around identity fraud being the most critical. Liveness-centric approach and authenticity cross-checks as the only options to prevent sophisticated identity fraud Addressing identity fraud is crucial, with 43% prioritizing it, according to Regula’s survey. To succeed in combating document fraud and counterfeiting, IDV vendors must go beyond basic checks and enable comprehensive cross-referencing of all the data. This will be one of the major trends when developing IDV solutions in the coming years. Cross-referencing all the data in the document, including biometric checks, makes it possible to identify inconsistencies that may signal fraud. For example, a fraudster might attempt to replac

Bibby Financial Services Chooses FGI T.R.U.S.T.™ for Strategic Partnership28.11.2023 09:00:00 CET | Press release

FGI Worldwide LLC (“FGI”), a global leader in commercial finance, today announced that the UK’s largest independent invoice finance provider, Bibby Financial Services (“BFS”), has chosen FGI T.R.U.S.T.™ as its software platform for bad debt protection management and administration. FGI T.R.U.S.T.™ is a cloud-based platform that combines technology with functionality to enable corporations, brokers, and lenders to maximize and automate the administration of credit insurance policies. BFS chose T.R.U.S.T.™ over other platforms due to its robust features and the team’s flexible, solutions-oriented approach to the partnership. The collaborative, multi-month implementation process was completed ahead of schedule. “BFS is a world-renowned leader in the financial services industry, and FGI is proud to support its continued advancement with our T.R.U.S.T.™ technology,” commented Sami Altaher, President of FGI. “This partnership is the latest step in FGI’s global expansion as lenders recognize